Devices driven by artificial intelligence algorithms are becoming more prevalent in healthcare, but reimbursement remains a challenge. Deborah Godes from McDermott+Consulting spoke to Market Pathways on the topic, offering insights for companies entering the coverage, coding, and payment trenches for AI tech in the latest "From the Experts" column.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Trial MyStrategist.com and unlock 7-days of exclusive subscriber-only access to MedTech Strategist & Market PathwaysStart Trial
While most medtech start-ups struggle to gain even single-digit market shares in their efforts against much larger competitors, Nevro has captured one-fifth of the spinal cord stimulation market, through an aggressive clinical trial strategy, novel technology, and the identification of new markets.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.Learn More
MedTech Europe’s survey of in vitro diagnostics companies points to big post-IVDR gaps. Excerpted from Pathways’ Picks September 8, 2021.